Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841700 | 0.90 | L3MBTL1 (0.69) | L3MBTL1MAPTLMNASMN1; SMN2ITGB3 | |
| SCHEMBL4837548 | 0.85 | L3MBTL1 (0.66) | L3MBTL1MAPTLMNASMN1; SMN2ITGB3 | |
| SCHEMBL3811564 | 0.83 | L3MBTL1 (0.80) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL6331080 | 0.82 | L3MBTL1 (0.71) | L3MBTL1MAPTLMNASMN1; SMN2TP53 | |
| SCHEMBL2170633 | 0.81 | ALOX5 (0.67) | SMN1; SMN2ALOX5 | |
| SCHEMBL8475955 | 0.81 | L3MBTL1 (0.73) | L3MBTL1MAPTLMNASMN1; SMN2ITGB3 | |
| SCHEMBL9272300 | 0.81 | L3MBTL1 (0.81) | L3MBTL1MAPTLMNASMN1; SMN2ITGB3 | |
| SCHEMBL9205258 | 0.80 | L3MBTL1 (0.75) | L3MBTL1MAPTLMNASMN1; SMN2ITGB3 | |
| SCHEMBL20299180 | 0.79 | L3MBTL1 (0.79) | L3MBTL1MAPTLMNASMN1; SMN2ITGB3 | |
| SCHEMBL20500014 | 0.79 | L3MBTL1 (0.74) | L3MBTL1MAPTLMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0938476-B1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-0994105-B1 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | PFIZER PROD INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1078924-B1 | Intermediates and a process for producing beta-adrenergic receptor agonists | PFIZER PROD INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6657063-B1 | (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment | PFIZER INC. | 2003-12-02 | — | — | US | disclosed |
| US-6441181-B1 | MAKING (4-(2-(2-(6-AMINOPYRIDIN-3-YL)-2(R)-HYDROXYETHYLAMINO)ETHOXY) PHENYLACETIC ACID; DEPROTECTION OF PYRROLE DERIVATIVE; INTERMEDIATES | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020045757-A1 | Compound and process for producing beta-adrenergic receptor agonist | SCOTT ROBERT W (US) | 2002-04-18 | — | — | US | disclosed |
| US-6297382-B1 | (4-(2-(2-(6-AMINOPYRIDIN-3-YL)-2(R)-HYDROXYETHYLAMINO)ETHOXY) PHENYLACETIC ACID, | PFIZER, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6291489-B1 | USEFUL IN THE SYNTHESIS OF CERTAIN .BETA.-ADRENERGIC RECEPTOR AGONISTS | PFIZER INC. | 2001-09-18 | — | — | US | disclosed |
| EP-1078924-A1 | Intermediates and a process for producing beta-adrenergic receptor agonists | Pfizer Products Inc. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6090942-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0994105-A2 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | Pfizer Products Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0938476-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0920864-A1 | Combination therapy including a specific beta-3 agonist and an anorectic agent | Pfizer Products Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998021184-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045757-A1 | Compound and process for producing beta-adrenergic receptor agonist | ADRB1, ADRB2, ADRA2B | L3MBTL1 4849/4885MAPT 3013/4885LMNA 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.